Cargando…

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

BACKGROUND: We evaluated Nix-TB trial data (NCT02333799, N = 109) to provide dosing recommendations to potentially minimize linezolid toxicity in patients with extensively drug-resistant tuberculosis. . METHODS: A pharmacokinetic model and toxicodynamic models for peripheral neuropathy, hemoglobin,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imperial, Marjorie Z, Nedelman, Jerry R, Conradie, Francesca, Savic, R M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles and Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9155613/ https://www.ncbi.nlm.nih.gov/pubmed/34604901 http://dx.doi.org/10.1093/cid/ciab699

Ejemplares similares

Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis
por: Padmapriyadarsini, Chandrasekaran, et al.
Publicado: (2022)

Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis
por: Mase, Anjeli, et al.
Publicado: (2022)

Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis
por: Bigelow, Kristina M, et al.
Publicado: (2020)

Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial
por: Solans, Belén P, et al.
Publicado: (2023)

Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia
por: Folan, Stephanie A, et al.
Publicado: (2018)

Linezolid-resistant Mycobacterium tuberculosis: Will it impact the tuberculosis elimination programme?
por: Bharadwaj, Renu
Publicado: (2021)

Linezolid for Treating Tuberculosis: A Delicate Balancing Act
por: Maartens, Gary, et al.
Publicado: (2015)

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis
por: Song, Taeksun, et al.
Publicado: (2015)

Safety and Outcomes of Linezolid Use for Nocardiosis
por: Davidson, Natalie, et al.
Publicado: (2020)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France
por: Jaspard, Marie, et al.
Publicado: (2020)

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2017)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
por: Dorazio, Joshua, et al.
Publicado: (2023)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus
por: Greene, Matthew H, et al.
Publicado: (2018)

Bedaquiline and Linezolid for Extensively Drug-Resistant Tuberculosis in Pregnant Woman
por: Jaspard, Marie, et al.
Publicado: (2017)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis Treatment
por: Keutzer, Lina, et al.
Publicado: (2023)

Therapeutic drug monitoring: linezolid too?
por: Richards, Guy A, et al.
Publicado: (2014)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

A Cross-sectional Analysis of Linezolid in Combination with Methadone or Buprenorphine as a Cause of Serotonin Toxicity
por: Traver, Edward C, et al.
Publicado: (2022)

Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients
por: Kawasuji, Hitoshi, et al.
Publicado: (2021)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial
por: Davis, Angharad G, et al.
Publicado: (2022)

Safety Profile of Linezolid in Older Adults With Renal Impairment: A Population-Based Retrospective Cohort Study
por: Bai, Anthony D, et al.
Publicado: (2022)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations
por: Chabala, Chishala, et al.
Publicado: (2021)

Evaluating adverse events in databases
por: Lovell, Katie, et al.
Publicado: (2023)

Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
por: Mathad, Jyoti S, et al.
Publicado: (2021)

Clinical Failures of Linezolid and Implications for the Clinical Microbiology Laboratory
por: Potoski, Brian A., et al.
Publicado: (2002)

Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign
por: Nyombayire, Julien, et al.
Publicado: (2022)

Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant Tuberculosis
por: Mockeliunas, Laurynas, et al.
Publicado: (2022)

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis
por: Zhang, Haoyue, et al.
Publicado: (2023)

Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies
por: Garcia-Prats, Anthony J., et al.
Publicado: (2019)

Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing
por: Susanto, Budi O, et al.
Publicado: (2019)

Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials
por: Imperial, Marjorie Z., et al.
Publicado: (2021)

Long-term Follow-up Reveals High Posttreatment Mortality Rate Among Patients With Extensively Drug-Resistant Tuberculosis in the Country of Georgia
por: Frank, Melanie, et al.
Publicado: (2019)

Risk Factors for CMV Viremia and Treatment-Associated Adverse Events Among Pediatric Hematopoietic Stem Cell Transplant Recipients
por: Heston, Sarah M, et al.
Publicado: (2021)

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gcqt0jkumaa59nolr8f0cciukn